IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo.

Details

Serval ID
serval:BIB_13A22B3E6D75
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo.
Journal
Inflammatory Bowel Diseases
Author(s)
Mudter J., Yu J., Zufferey C., Brüstle A., Wirtz S., Weigmann B., Hoffman A., Schenk M., Galle P.R., Lehr H.A., Mueller C., Lohoff M., Neurath M.F.
ISSN
1536-4844 (Electronic)
ISSN-L
1078-0998
Publication state
Published
Issued date
2011
Volume
17
Number
6
Pages
1343-1358
Language
english
Abstract
Background: The transcription factor IRF4 is involved in several T-cell-dependent chronic inflammatory diseases. To elucidate the mechanisms for pathological cytokine production in colitis, we addressed the role of the IRF transcription factors in human inflammatory bowel disease (IBD) and experimental colitis.Methods: IRF levels and cytokine production in IBD patients were studied as well as the effects of IRF4 deficiency in experimental colitis.Results: In contrast to IRF1, IRF5, and IRF8, IRF4 expression in IBD was augmented in the presence of active inflammation. Furthermore, IRF4 levels significantly correlated with IL-6 and IL-17 mRNA expression and to a lesser extent with IL-22 mRNA expression in IBD. To further explore the role of IRF4 under in vivo conditions, we studied IRF4-deficient and wildtype mice in experimental colitis. In contrast to DSS colitis, IRF4 deficiency was protective in T-cell-dependent transfer colitis associated with reduced ROR alpha/gamma t levels and impaired IL-6, IL-17a, and IL-22 production, suggesting that IRF4 acts as a master regulator of mucosal Th17 cell differentiation. Subsequent mechanistic studies using database analysis, chromatin immunoprecipitation, and electrophoretic mobility shift assays identified a novel IRF4 binding site in the IL-17 gene promoter. Overexpression of IRF4 using retroviral infection induced IL-17 production and IL-17 together with IL-6 induced ROR gamma t expression.Conclusions: IRF4 can directly bind to the IL-17 promotor and induces mucosal ROR gamma t levels and IL-17 gene expression thereby controlling Th17-dependent colitis. Targeting of this molecular mechanism may lead to novel therapeutic approaches in human IBD.
Pubmed
Web of science
Create date
30/05/2011 9:56
Last modification date
20/08/2019 12:42
Usage data